{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:44:55Z","timestamp":1776721495965,"version":"3.51.2"},"reference-count":13,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Antecedentes: La urticaria solar es una enfermedad poco frecuente, inducida por la exposici\u00f3n a la radiaci\u00f3n ultravioleta. Si bien es un cuadro de curaci\u00f3n espont\u00e1nea, al igual que diferentes tipos de dermatosis suele afectar la calidad de vida de los pacientes. Se reporta el caso de una paciente con urticaria solar tratada exitosamente con omalizumab.\nReporte de caso: Paciente femenina de 36 a\u00f1os, con antecedentes al\u00e9rgicos, que acudi\u00f3 a consulta por un cuadro caracterizado por ronchas pruriginosas en \u00e1reas fotoexpuestas, de cuatro a\u00f1os de evoluci\u00f3n. La determinaci\u00f3n de IgE s\u00e9rica result\u00f3 elevada (507 UI\/ml), y los anticuerpos antinucleares y el factor reumatoide fueron negativos. El tratamiento inicial con levocetirizina (hasta 20 mg\/d\u00eda) y fotoprotecci\u00f3n fracas\u00f3, con un Urticarial Control Test (UCT) de 10. Se agreg\u00f3 omalizumab (300 mg\/4 semanas), con lo que se logr\u00f3 el control completo de la alteraci\u00f3n (UCT 16), luego de cinco meses, permitiendo reducir la dosis y el intervalo del f\u00e1rmaco. Sin embargo, los episodios en temporada de primavera (UCT 6) obligaron a reinstaurar la dosis inicial para recuperar el control total de la enfermedad.\nConclusi\u00f3n: Omalizumab es un anticuerpo monoclonal anti-IgE, que parezca eficaz como de segunda l\u00ednea para el tratamiento de pacientes con urticaria solar que no responden al protocolo con antihistam\u00ednicos sist\u00e9micos de manera off label.\nPalabras clave: Urticaria solar; Radiaci\u00f3n ultravioleta; Calidad de vida; Prurito; IgE; Anticuerpos antinucleares; Factor reumatoide; Omalizumab; Antihistam\u00ednicos.<\/jats:p>","DOI":"10.29262\/ram.v72i4.1529","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:35:40Z","timestamp":1767828940000},"page":"372-375","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Omalizumab en el tratamiento de la urticaria solar grave &lt;\/b&gt;","&lt;b&gt;Omalizumab for the treatment of severe solar urticaria &lt;\/b&gt;"],"prefix":"10.29262","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-918X","authenticated-orcid":false,"given":"Santiago","family":"Pereda","sequence":"first","affiliation":[{"name":"Hospital Italiano de Buenos Aires, CABA, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9670-6566","authenticated-orcid":false,"given":"Ana Clara","family":"Ana Clara","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, CABA, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8734-4604","authenticated-orcid":false,"given":"Nadia","family":"Nadia","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, CABA, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-8449","authenticated-orcid":false,"given":"Carla","family":"Carla","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, CABA, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Luis","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, CABA, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"65497","doi-asserted-by":"crossref","unstructured":"1. Garc\u00eda-D\u00edez I, Curto-Barredo L, Weller K, Pujol R, et al. Adaptaci\u00f3n Transcultural Del Cuestionario Urticaria Control Test Del Alem\u00e1n al Castellano. Actas Dermo-Sifiliograficas 2015; 106 (9): 746-52.","DOI":"10.1016\/j.ad.2015.05.009"},{"key":"65498","doi-asserted-by":"crossref","unstructured":"2. Spertino J, Curto-Barredo L, Rozas-Mu\u00f1oz E, Figueras-Nart I, et al. Algoritmo de Tratamiento Con Omalizumab En Urticaria Cr\u00f3nica Espont\u00e1nea.\u201d Actas Dermo-Sifiliograficas 2018; 109 (9): 771-76.","DOI":"10.1016\/j.ad.2018.07.005"},{"key":"65499","doi-asserted-by":"crossref","unstructured":"3. McSweeney SM, Sarkany R, Fassihi H, Tziotzios C, et al. Pathogenesis of Solar Urticaria: Classic Perspectives and Emerging Concepts. Exp Dermatol 2022; 31 (4): 586-93.","DOI":"10.1111\/exd.14493"},{"key":"65500","doi-asserted-by":"crossref","unstructured":"4. Steven G, Elsner P. Solar Urticaria. J Der Deutschen Dermatol Gesellschaft 2015; 13 (12): 125053.","DOI":"10.1111\/ddg.12809"},{"key":"65501","doi-asserted-by":"crossref","unstructured":"5. Torsten Z, Abdul Latiff AH, Abuzakouk M, Aquilina S, et al. The International EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI Guideline for the Definition, Classification, Diagnosis, and Management of Urticaria. Allergy 2022; 77 (3): 734-66.","DOI":"10.1111\/all.15090"},{"key":"65502","doi-asserted-by":"crossref","unstructured":"6. Folci M, Ramponi G, Brunetta E. A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments through Pathogenesis. Adv Exp Med Biol 2021; 1326: 111-37.","DOI":"10.1007\/5584_2020_612"},{"key":"65503","doi-asserted-by":"crossref","unstructured":"7. Antia C, Baquerizo K, Korman A, Alikhan A, et al. Urticaria: A Comprehensive Review: Treatment of Chronic Urticaria, Special Populations, and Disease Outcomes. J Am Acad Dermatol 2018; 79 (4): 617-33.","DOI":"10.1016\/j.jaad.2018.01.023"},{"key":"65504","doi-asserted-by":"crossref","unstructured":"8. Chicharro P, Rodr\u00edguez-Jim\u00e9nez P, Capusan TM, Herrero-Moyano M, et al. Inducci\u00f3n de fototolerancia con ultravioleta B de banda estrecha en urticaria solar. Actas Dermo-Sifiliogr\u00e1ficas 2019; 109, (10): 888-892.","DOI":"10.1016\/j.ad.2018.06.005"},{"key":"65505","doi-asserted-by":"crossref","unstructured":"9. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007; 63 (5): 548-61.","DOI":"10.1111\/j.1365-2125.2006.02803.x"},{"key":"65506","doi-asserted-by":"crossref","unstructured":"10. Jia HX, He YL. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Ther 2020; 27(5): 455-467.","DOI":"10.1097\/MJT.0000000000000912"},{"key":"65507","doi-asserted-by":"crossref","unstructured":"11. Casanova-Esquembre A, Lorca-Spr\u00f6hnle J, Pe\u00f1uelas-Leal R, P\u00e9rez-Ferriols A. Solar Urticaria and Omalizumab: A Retrospective Case-Control Study and Follow-Up. Actas Dermo-Sifiliograficas 2024; 115 (9): 931-32.","DOI":"10.1016\/j.ad.2023.04.044"},{"key":"65508","doi-asserted-by":"crossref","unstructured":"12. Morgado-Carrasco D, Gi\u00e1caman-Von der Weth M, Fust\u00e1-Novell X, Podlipnik S, et al. Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab. J Am Acad Dermatol 2023; 88 (5): 1110-1111.","DOI":"10.1016\/j.jaad.2019.05.070"},{"key":"65509","doi-asserted-by":"crossref","unstructured":"13. Baliu-Piqu\u00e9 C, Aguilera Peir\u00f3 P. Three cases of solar urticaria successfully treated with omalizumab. J Eur Acad Dermatol Venereol 2016; 30 (4): 704-6.","DOI":"10.1111\/jdv.13001"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1529\/2798","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1529\/2821","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1529\/2798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:56:50Z","timestamp":1776718610000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,19]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v72i4.1529","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"value":"2448-9190","type":"electronic"},{"value":"0002-5151","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}